PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

valganciclovir Side Effects

The reactions most often reported to the FDA for valganciclovir (also sold as Valcyte), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

18,056
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of valganciclovir come from 18,056 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 18,056 reports to the FDA Adverse Event Reporting System (FAERS) for valganciclovir (Valcyte): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

18,056

Reports Mentioning Death

3,133

17.4% of reports — not proof the medicine caused the death

Hospitalizations

8,858

49.1% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

CYTOMEGALOVIRUS INFECTION
1,756
NEUTROPENIA
1,096
PYREXIA
939
DIARRHOEA
916
LEUKOPENIA
914
ACUTE KIDNEY INJURY
797
DEATH
754
CYTOMEGALOVIRUS VIRAEMIA
722
PANCYTOPENIA
662
DRUG RESISTANCE
637
TRANSPLANT REJECTION
631
ANAEMIA
621
THROMBOCYTOPENIA
605
PNEUMONIA
587
NAUSEA
501
SEPSIS
497
RENAL IMPAIRMENT
477

Who Reports Side Effects

Gender Distribution

Female 6,365 (40%)
Male 9,377 (59%)
Unknown 39

Age Distribution

0-17 1,514 (12%)
18-44 3,269 (25%)
45-64 5,201 (40%)
65-74 2,466 (19%)
75+ 566 (4%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 3,133 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 754
SEPSIS 300
CYTOMEGALOVIRUS INFECTION 256
PANCYTOPENIA 255
SEPTIC SHOCK 234
ACUTE KIDNEY INJURY 227
MULTIPLE ORGAN DYSFUNCTION SYNDROME 214
RESPIRATORY FAILURE 213
PNEUMONIA 206
NEUTROPENIA 154
THROMBOCYTOPENIA 147
LEUKOPENIA 146
PYREXIA 146
CYTOMEGALOVIRUS INFECTION REACTIVATION 132
DIARRHOEA 128
RENAL FAILURE 119
MYELOSUPPRESSION 105
CYTOMEGALOVIRUS VIRAEMIA 100

Reactions in Hospitalization Reports

Top reactions in 8,858 reports where hospitalization was an outcome.

Reaction Reports
PYREXIA 736
CYTOMEGALOVIRUS INFECTION 710
DIARRHOEA 658
NEUTROPENIA 585
ACUTE KIDNEY INJURY 531
LEUKOPENIA 514
ANAEMIA 461
PANCYTOPENIA 420
PNEUMONIA 409
THROMBOCYTOPENIA 382
NAUSEA 367
VOMITING 350
TRANSPLANT REJECTION 347
SEPSIS 339
BLOOD CREATININE INCREASED 318
URINARY TRACT INFECTION 300
RENAL IMPAIRMENT 299
DRUG INTERACTION 285

Compare valganciclovir vs acyclovir →

What the FAERS Data Reveals About valganciclovir Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 18,056 voluntary reports linked to valganciclovir and its brand equivalents (Valcyte), spanning 2004 through 2025. Of those, 3,133 (17.4%) listed death as an outcome and 8,858 (49.1%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 40% were female and 59% male; age distribution skews toward 45-64, with 5,201 reports in that bracket. The single most reported reaction is cytomegalovirus infection with 1,756 submissions, followed by neutropenia and pyrexia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.